A Pre-Approval Information Exchange (PIE) Webinar, presented by Intellia Therapeutics.

This presentation contains information about the investigational product lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002) for the treatment of hereditary angioedema (HAE). Lonvo-z is investigational, has not received FDA-approval, and safety and efficacy have not been established. This presentation is intended only for payers, formulary committees or other similar entities responsible for the selection of drugs for coverage or reimbursement.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP CE Webinar.

Through a moderated panel discussion featuring experts from managed care, industry, and health policy, speakers will examine key themes related to the value, communication, credibility, and application of Patient Experience Data in coverage and formulary decision-making. The session will conclude with practical recommendations and future directions for advancing the meaningful use of patient experience data in payer decision-making.

An AMCP Market Insights Webinar.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare immune-mediated neuropathy that can result in significant long-term disability if diagnosis and treatment are delayed. In this AMCP Market Insights webinar, Dr. Ehtesham Khalid reviews recent advances in the understanding of CIDP, including emerging insights into disease pathophysiology, diagnostic challenges, current standards of care, and investigational therapies. Drawing on findings from AMCP's May 2026 Market Insights roundtable, the program highlights issues relevant to managed care professionals, including treatment timing, evolving mechanisms of action, and considerations for future coverage and access decisions.

An AMCP Webinar.

Since its introduction in 2000, the AMCP Format for Formulary Submissions has become the primary tool for manufacturers to share safety, efficacy, and value data with health care decision-makers (HCDMs) as they consider products for coverage and formulary placement. In October, AMCP launched Format version 6.0.

This spotlight session will highlight updates made in version 6.0, including a discussion with an HCDM on how these updates will impact their review process. Future updates to the Format will also be discussed.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Apnimed.

Obstructive Sleep Apnea (OSA) is common, costly, and rarely just sleep apnea — it raises cardiovascular, metabolic, and neurocognitive risk. Decades under the medical benefit, OSA therapies mechanically target obstruction instead of a key neuromuscular cause. This PIE webinar previews the neuromuscular mechanism behind airway collapse, gaps in the current landscape, and a new approach targeting airway muscle tone. Learn about an investigational oral therapy before it hits your P&T agenda.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have note been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Genentech.

Join us for a Pre-Approval Information Exchange (PIE) on giredestrant, an investigational oral SERD under evaluation for adjuvant ER+/HER2- stage I–III breast cancer at intermediate to high-risk of recurrence. This session reviews eBC disease burden, clinical parameters from the Phase 3 lidERA study, and population-level Treatment Impact Model (TIM) considerations to assist payers with early budget and health plan forecasting.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie.

The objective of this Pharmacokinetic/Pharmacokinetic (PK/PD) analysis is to evaluate Bruton's Tyrosine Kinase (BTK) occupancy at doses included in the US Prescribing Information (USPI) dose modifications for adverse reactions recommendations.

• Review the dose modification guidance for adverse reactions included in the US Prescribing Information.
• Explain the PK/PD findings showing BTK occupancy at doses included in the USPI dose modifications for adverse reactions.